Skip to content
Home/Companies/Biotech/Origo Biopharma

Origo Biopharma

Biotech·Spain·Exited 2021·Held 1yr
Entry
2020
Hold
1yr
Exit
2021

Who owns Origo Biopharma?

Origo Biopharma was owned by Asabys Partners through Sabadell Asabys Health Innovation Investments (2019 vintage) from 2020 to 2021, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-09

Asabys Partners
Investor
Asabys Partners
Sabadell Asabys Health Innovation Investments · 2019 · Life Sciences VC

Key facts

HQSpain
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2021

More from Sabadell Asabys Health Innovation Investments

Other portfolio companies in the same fund.

Accure Therapeutics
Active
BiotechSpain· 2025
Qida
Active
HealthTechSpain· 2025
XRHealth
XRHealth
Active
HealthTechUnited States· 2023
Splice Bio
Splice Bio
Active
BiotechSpain· 2022
Agomab
Agomab
Exited 2026
BiotechBelgium· 2021
INBRAIN Neuroelectronics
INBRAIN Neuroelectronics
Active
MedTechSpain· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Origo Biopharma

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Origo Biopharma.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue